Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Shares Outstanding (Diluted Average) (2017 - 2025)

Historic Shares Outstanding (Diluted Average) for Coherus Oncology (CHRS) over the last 9 years, with Q3 2025 value amounting to $116.2 million.

  • Coherus Oncology's Shares Outstanding (Diluted Average) rose 88.45% to $116.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.2 million, marking a year-over-year increase of 88.45%. This contributed to the annual value of $114.8 million for FY2024, which is 2194.91% up from last year.
  • As of Q3 2025, Coherus Oncology's Shares Outstanding (Diluted Average) stood at $116.2 million, which was up 88.45% from $116.1 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Shares Outstanding (Diluted Average) high stood at $116.2 million for Q3 2025, and its period low was $72.8 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $93.5 million, with a median of $87.3 million in 2023.
  • Per our database at Business Quant, Coherus Oncology's Shares Outstanding (Diluted Average) tumbled by 1477.62% in 2021 and then soared by 4223.66% in 2024.
  • Over the past 5 years, Coherus Oncology's Shares Outstanding (Diluted Average) (Quarter) stood at $75.4 million in 2021, then rose by 2.89% to $77.6 million in 2022, then rose by 21.3% to $94.2 million in 2023, then increased by 21.95% to $114.8 million in 2024, then grew by 1.22% to $116.2 million in 2025.
  • Its last three reported values are $116.2 million in Q3 2025, $116.1 million for Q2 2025, and $115.9 million during Q1 2025.